Physician profile
Sin Ty
NPI 1457783797
$9,506.66
in general payments reported to CMS, 2019-2025
31 companies · $1,842 in 2025
The $1,842 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,088 · 2022: $2,190 · 2023: $2,038 · 2024: $1,348 · 2025: $1,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,149 · Education: $79.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,148.75 |
| Education | $79.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,162.24 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,703.98 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $583.34 | 2021-2024 | Zeposia |
| Novo Nordisk INC | $496.16 | 2021-2023 | Wegovy |
| Qol Medical, LLC | $450.95 | 2021-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $392.14 | 2021-2025 | |
| Ardelyx, INC. | $386.93 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $374.38 | 2021-2025 | Entyvio |
| Genzyme Corporation | $341.08 | 2022-2025 | |
| Madrigal Pharmaceuticals | $272.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $224.97 | 2021-2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $220.74 | 2021-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $194.17 | 2021-2023 | |
| Gilead Sciences, INC. | $194.00 | 2021-2025 | |
| Celgene Corporation | $179.24 | 2021-2024 | Zeposia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $160.79 | 2024-2025 | Zenpep, Vowst |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $132.01 | 2021-2025 | Suflave |
| Merck Sharp & Dohme LLC | $129.25 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Lilly USA, LLC | $109.98 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $99.74 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $98.02 | 2021-2022 | |
| Daiichi Sankyo INC. | $90.76 | 2022 | |
| Celltrion USA INC. | $78.92 | 2024 | Zymfentra, Vegzelma |
| Redhill Biopharma INC. | $47.40 | 2022 | |
| Pfizer INC. | $39.41 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $20.94 | 2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.66 | 2024 | Cyltezo |
| Alfasigma USA, INC. | $15.05 | 2021 | |
| Axonics, INC. | $14.61 | 2024 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sin Ty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.